Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer.

Su Z, Dannull J, Yang BK, Dahm P, Coleman D, Yancey D, Sichi S, Niedzwiecki D, Boczkowski D, Gilboa E, Vieweg J.

J Immunol. 2005 Mar 15;174(6):3798-807.

2.

Expression of FOXP3 mRNA is not confined to CD4+CD25+ T regulatory cells in humans.

Morgan ME, van Bilsen JH, Bakker AM, Heemskerk B, Schilham MW, Hartgers FC, Elferink BG, van der Zanden L, de Vries RR, Huizinga TW, Ottenhoff TH, Toes RE.

Hum Immunol. 2005 Jan;66(1):13-20.

PMID:
15620457
3.

The molecular program induced in T cells undergoing homeostatic proliferation.

Goldrath AW, Luckey CJ, Park R, Benoist C, Mathis D.

Proc Natl Acad Sci U S A. 2004 Nov 30;101(48):16885-90. Epub 2004 Nov 17.

4.

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.

Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W.

Nat Med. 2004 Sep;10(9):942-9. Epub 2004 Aug 22.

5.

Functional assay for human CD4+CD25+ Treg cells reveals an age-dependent loss of suppressive activity.

Tsaknaridis L, Spencer L, Culbertson N, Hicks K, LaTocha D, Chou YK, Whitham RH, Bakke A, Jones RE, Offner H, Bourdette DN, Vandenbark AA.

J Neurosci Res. 2003 Oct 15;74(2):296-308.

PMID:
14515359
6.

Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells.

Su Z, Dannull J, Heiser A, Yancey D, Pruitt S, Madden J, Coleman D, Niedzwiecki D, Gilboa E, Vieweg J.

Cancer Res. 2003 May 1;63(9):2127-33.

7.

Diphtheria toxin conjugate therapy of cancer.

Frankel AE, Powell BL, Lilly MB.

Cancer Chemother Biol Response Modif. 2002;20:301-13. Review.

PMID:
12703211
8.

Inhibition of human CD4(+)CD25(+high) regulatory T cell function.

Baecher-Allan C, Viglietta V, Hafler DA.

J Immunol. 2002 Dec 1;169(11):6210-7.

9.

Characterization of human CD25+ CD4+ T cells in thymus, cord and adult blood.

Wing K, Ekmark A, Karlsson H, Rudin A, Suri-Payer E.

Immunology. 2002 Jun;106(2):190-9.

10.

Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation.

Woo EY, Yeh H, Chu CS, Schlienger K, Carroll RG, Riley JL, Kaiser LR, June CH.

J Immunol. 2002 May 1;168(9):4272-6.

11.

Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors.

Heiser A, Coleman D, Dannull J, Yancey D, Maurice MA, Lallas CD, Dahm P, Niedzwiecki D, Gilboa E, Vieweg J.

J Clin Invest. 2002 Feb;109(3):409-17.

12.

CD4(+) regulatory T cells.

Read S, Powrie F.

Curr Opin Immunol. 2001 Dec;13(6):644-9. Review.

PMID:
11677084
13.

Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses.

Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP, Toes RE, Offringa R, Melief CJ.

J Exp Med. 2001 Sep 17;194(6):823-32.

14.

Dendritic cells as a tool to induce anergic and regulatory T cells.

Jonuleit H, Schmitt E, Steinbrink K, Enk AH.

Trends Immunol. 2001 Jul;22(7):394-400. Review.

PMID:
11429324
15.

Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.

Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, Rubin SC, Kaiser LR, June CH.

Cancer Res. 2001 Jun 15;61(12):4766-72.

16.

Certified professionals: CD4(+)CD25(+) suppressor T cells.

Shevach EM.

J Exp Med. 2001 Jun 4;193(11):F41-6. No abstract available.

17.
18.

Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma.

Olsen E, Duvic M, Frankel A, Kim Y, Martin A, Vonderheid E, Jegasothy B, Wood G, Gordon M, Heald P, Oseroff A, Pinter-Brown L, Bowen G, Kuzel T, Fivenson D, Foss F, Glode M, Molina A, Knobler E, Stewart S, Cooper K, Stevens S, Craig F, Reuben J, Bacha P, Nichols J.

J Clin Oncol. 2001 Jan 15;19(2):376-88.

PMID:
11208829
19.

Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA.

Heiser A, Maurice MA, Yancey DR, Wu NZ, Dahm P, Pruitt SK, Boczkowski D, Nair SK, Ballo MS, Gilboa E, Vieweg J.

J Immunol. 2001 Mar 1;166(5):2953-60.

Supplemental Content

Support Center